|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Indications,limitations and maneuvers to enable extended hepatectomy:Current trends显示文摘The liver is a solid organ with a wide variety of primary benign or malignant tumors as well as metastatic lesions.Surgical resection of these tumors remains the only curative modality.Several limitations,however,do not allow the performance of these operations.This review evaluates the indications and limitations regarding these extended hepatic resections,as well as describing all the manipulations that increase the candidates for such operations.A thorough review of the literature was performed in order to define indications for extended hepatectomy,as well as to present all methods that contribute to increasing the volume of the future remnant liver.The role of portal vein ligation,portal vein embolization,two-stage hepatectomy,and in situ liver transection are evaluated in the setting of indications and results.Extended hepatectomies are a necessity due to oncological reasons.All methods developed in order to increase the volume of the remnant liver are safe and efficient.in situ liver transection is a novel and revolutionary two-step procedure for extended hepatic resections.Further clinical studies are required to estimate long-term results and the oncological basis of this technique. | Dimitrios Dimitroulis Petros Tsaparas Serena Valsami Dimitrios Mantas Eleftherios Spartalis Charalampos Markakis Gregory Kouraklis | 2014 | World Journal of Gastroenterology2014，20，24： | 4 |
| 2 | Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen显示文摘Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450(CYP) enzymes, in particular the CYP2D6 isoform. CYP2D6*4 is one of the most frequent alleles associated with loss of enzymatic activity. The incidence of CYP2D6*4 among Caucasians is estimated up to 27%, while it is present in up to 90% of all poor metabolizers within the Caucasian population. The hypothesis under question is whether the presence of one or two non-functioning(null) alleles predicts an inferior outcome in postmenopausal women with breast cancer receiving adjuvant treatment with tamoxifen. The numerous existing studies investigating the association of CYP2D6 with treatment failure in breast cancer are inconsistent and give rather conflicting results. Currently, routine CYP2D6 testing among women with breast cancer is not recommended and the significance of CYP2D6 phenotype in decision making regarding the administration of tamoxifen is unclear. The present study summarizes current literature regarding clinical studies on CYP2D6*4, par-ticularly in terms of response to tamoxifen therapy and breast cancer outcome. | Christos Markopoulos Stylianos Kykalos Dimitrios Mantas | 2014 | World Journal of Clinical Oncology2014，5，3： | 4 |
| 3 | Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells显示文摘 | Panagiotis Apostolou Maria Toloudi Eleni Ioannou Eleni Kourtidou Marina Chatziioannou Asir Kopic Dimitrios Komiotis Christos Kiritsis Stella Manta Ioannis Papasotiriou | 2013 | Journal of Receptors and Signal Transduction2013，，6： | 1 |
| 4 | Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells显示文摘 | Panagiotis Apostolou Maria Toloudi Eleni Ioannou Eleni Kourtidou Marina Chatziioannou Asir Kopic Dimitrios Komiotis Christos Kiritsis Stella Manta Ioannis Papasotiriou | 2013 | Journal of Receptors and Signal Transduction2013，，6： | 1 |
| 5 | Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas显示文摘Epigenetic mechanisms,such as DNA methylation and histone modifications(e.g.,acetylation and deacetylation),are strongly implicated in the carcinogenesis of various malignancies.During transcription,the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation.These processes are regulated by histone acetyltransferases(HATs)and histone deacetylases(HDACs),respectively.HDAC inhibitors(HDACis)have been developed as promising therapeutic agents,to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options.Mechanistically,these agents affect many intracellular pathways,including cell cycle arrest,apoptosis and differentiation,and their mechanism of action mainly depends on the type of cancer.Currently,five HDACis have been approved for the treatment of several hematological malignancies(e.g.,T-cell lymphoma subtypes and multiple myeloma);while,many of them are tested for further therapeutic indications in solid tumors(e.g.,colorectal,thyroid,breast,lung and pancreatic cancer).Herein,we review the literature and gather all available evidence,from in vitro and in vivo data to clinical trial results,that recognizes the antitumor activity of HDACis on pheochromocytomas and paragangliomas;and supports their clinical implementation in the treatment of these rare neuroendocrine tumors at metastatic setting. | ASPASIA MANTA SPYRIDON KAZANAS STEFANOS KARAMAROUDIS HELEN GOGAS DIMITRIOS C.ZIOGAS | 2022 | Oncology Research2022，30，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员